MSI 1857
Latest Information Update: 08 Aug 2007
Price :
$50 *
At a glance
- Originator Genaera Corporation
- Class Antineoplastics; Peptides
- Mechanism of Action Cell membrane modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 17 Feb 2006 No development reported - Preclinical for Cancer in USA (unspecified route)
- 31 Dec 2001 This compound is still in active development
- 28 Mar 2001 Magainin Pharmaceuticals is now called Genaera Corporation